Opens in a new tab

Sanofi v Accord Healthcare (CFI, ORD_69482/2024, 15 September 2025)

Date15 September 2025
CourtCFI
DivisionMunich (DE) Local Division
Type of actionInfringement Action
Registry referenceACT_16120/2024 · ORD_69482/2024
PartiesSanofi-Aventis GmbH, Sanofi A/S, Sanofi Mature IP, Sanofi-Aventis France, Sanofi B.V., Sanofi - Produtos Farmaceuticos Lda, Sanofi Winthrop…

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 15 September 2025 under Rule 105.5 RoP, following the second interim conference of 12 September 2025, the judge-rapporteur of the Munich Local Division organises the hearing of the four infringement actions brought by Sanofi group companies on European patent EP 2 493 466 against Accord Healthcare, STADAPHARM, Reddy Pharma and Zentiva (UPC_CFI_145/2024 to UPC_CFI_148/2024), together with the related counterclaims. The order, common to the four proceedings, sets the oral hearing for 14 to 17 October 2025, provides for two party experts to be heard and rules on late filings by Zentiva.

Question

How should the oral phase of four parallel proceedings be organised, and may evidence filed late by Zentiva be admitted?

Decision

The four counterclaims are heard together and the four infringement actions separately. Two party experts, one for Sanofi and one for all the defendants, are to be heard on 14 October 2025 on the TROPIC phase III study and the reasonable expectation of success. To the defendants’ objection that legal questions may not be put to experts, the judge-rapporteur answers that hearing them will help the panel decide the legal question of obviousness, with the parties free to question them within the limits of Rule 178.5 RoP. Zentiva’s declaration D116 is admitted, the second affidavit D117 of 8 August 2025 is excluded, since an application to file further evidence could have been made earlier. The parties may comment by 8 October 2025 on the written reasons of the EPO Board of Appeal, which upheld the patent after the hearing of 2 to 4 June 2025.

Key points for practice

Provisions applied

Rules of Procedure
Rules 102.2, 103, 105.5, 115, 178.5, 333 and 355

Related decisions

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Patent infringement action, Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.

Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.

Publications by Matthieu Dhenne: Pleading the Long Arm: What a UPC Statement of Claim Must Carry Beyond Jurisdiction, The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Infringement Action
Outcome (Dhenne Avocats summary)
Le juge-rapporteur fixe l’audience des quatre procédures Sanofi du 14 au 17 octobre 2025, prévoit l’audition de deux experts de parties et écarte le second affidavit tardif de Zentiva, en admettant sa déclaration D116.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 2 493 466
Novel antitumoral use of cabazitaxel
recorded proprietor: Sanofi SA
Mentioned in the analysis (role not qualified)
Also mentioned in 12 other decision(s): Sanofi v Reddy Pharma (CFI, 12 December 2025) · Zentiva France v Sanofi Mature IP (CFI, 24 January 2025) · Accord Healthcare v Sanofi (Paris Judicial Court, RG 21/06416, 2024) · Sanofi v Accord Healthcare (CFI, ORD_69480/2024, 15 September 2025) · Sanofi v Accord Healthcare (CFI, 17 July 2025) · Sanofi v Zentiva France (CFI, 27 June 2025) · Sanofi v Accord Healthcare (CFI, 8 May 2025) · Medac v Sanofi Mature IP (CFI, 19 March 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.